Visioneering Technologies Reported Successful Myopia Trial
The three-year PROTECT clinical trial showed reduced myopia progression in children using NaturalVue contact lenses.
Updated on Sept. 30, 2026 in Children’s Health
Live Poll
Do you trust new medical device trial results to guide your child's eye care decisions?
Visioneering Technologies has completed its three-year PROTECT clinical trial, which evaluated the NaturalVue Multifocal 1 Day contact lens for children. The study, which included 102 participants, demonstrated effectiveness in slowing myopia progression and axial elongation compared to a virtual control group.
Why it matters
The findings provide clinical evidence for contact lens-based interventions to manage childhood myopia. By reducing axial growth, the lens may help keep children within emmetropic benchmarks, potentially limiting the long-term vision risks associated with severe nearsightedness.
The PROTECT trial enrolled 102 children aged 7 to 13, with 59% of those using the lenses progressing 0.25 diopters or less annually. Additionally, 55% of the lens-wearing cohort achieved axial growth consistent with emmetropic benchmarks.
The players
Visioneering Technologies
This is an eye care company based in Alpharetta, Georgia, that specializes in optical products for myopia management.
American Academy of Optometry
This is a professional association that hosts an annual meeting for eye care professionals to review the latest clinical research.
The details
Researchers at trial sites across the United States, Canada, Hong Kong, and Singapore tracked refractive error and eye growth over 36 months, adjusting data for factors including age, sex, and ethnicity. The results were officially presented on September 30, 2026, at the American Academy of Optometry annual meeting in Anaheim, California.
Timeline
The PROTECT clinical trial was conducted over a three-year period from 2023 through 2026.
Study results were presented on September 30, 2026, in Anaheim, California.
The Big Picture
This study contributes to the growing body of research validated by the PROTECT clinical trial, reflecting a shift in pediatric eye care toward proactive myopia management rather than simple vision correction. It provides concrete evidence for optical interventions that aim to alter the physiological development of the eye.
Parents and patients should discuss these findings with their eye care providers to determine if multifocal contact lenses are a suitable treatment option based on current myopia progression. Individual results may vary based on age and baseline refractive values, necessitating professional clinical assessment.
The takeaway
Proactive myopia management in children is increasingly supported by clinical data focused on slowing axial elongation. Families concerned about vision changes should consult with specialists to review the latest optical solutions that extend beyond standard prescription glasses.
Further reading
For more information on eye health advancements, visit the Children’s Health section.
More information
Review the full study findings and company information on the Visioneering Technologies company website.
Live Poll
Do you trust new medical device trial results to guide your child's eye care decisions?
